Related by context. All words. (Click for frequent words.) 77 Phase #b/#a clinical 75 phase IIa clinical 73 Phase IIIb clinical 73 phase IIb clinical 73 Daclizumab 73 phase IIa 72 Phase Ib clinical 72 Pivotal Phase III 72 Combination REOLYSIN R 72 randomized controlled multicenter 72 Phase 1b clinical 72 BRIM3 72 Phase Ib II 72 Completes Patient Enrollment 72 Initiates Phase III 72 LymphoStat B belimumab 71 acyclovir Lauriad R 71 FOLOTYN ® 71 lintuzumab SGN 71 Initiates Phase II 71 APEX PD 71 PF # [002] 71 BRIM2 71 XL# anticancer compounds 71 phase Ib clinical 71 evaluating tivozanib 71 Cloretazine ® 71 dose escalation clinical 70 Achieves Primary Endpoint 70 Tramiprosate ALZHEMED TM 70 Initiate Phase 70 compound INCB# 70 LymphoStat B TM 70 randomized Phase IIb 70 INSPIRE Trial Phase III 70 Phase 1a clinical 70 rALLy clinical trial 70 AVN# Phase 70 multicenter Phase II 70 Panzem R 70 Begins Dosing 70 Initiate Phase II 70 Phase IIb III 70 Vicriviroc 70 SNT-MC#/idebenone 70 MKC# MT 70 oral ridaforolimus 70 Phase III multicenter 69 registrational Phase 69 Randomized Phase II 69 treatment naive genotype 69 induced macular edema 69 Initiates Enrollment 69 Aflibercept 69 Hsp# Inhibitor 69 novel VDA molecule 69 Oral Fingolimod 69 Meets Primary Endpoint 69 Bayer HealthCare Onyx Pharmaceuticals 69 Omacetaxine 69 randomized controlled Phase 69 MKC# 69 MAGE A3 ASCI 69 Aryplase 69 Phase 2b Clinical Trial 69 human IgG1 monoclonal 69 HuMax TAC 69 retinal vein occlusion induced 69 candidate AQ4N 69 initiated Phase Ib 69 sapacitabine CYC# 69 placebo controlled Phase III 69 CHAMPION PCI 69 ENDEAVOR III 68 EXPLORE Xa 68 Phase 1b clinical trials 68 humanized interleukin 6 68 refractory chronic lymphocytic 68 novel orally inhaled 68 Personalized Immunotherapy 68 pharmacogenomic translational research 68 forodesine 68 Phase IIb trials 68 TELINTRA R 68 Phase IIa clinical 68 Pirfenidone 68 ENESTnd 68 CCX# B 68 SUTENT ® 68 VEGFR2 inhibitor 68 Safinamide 68 Severe Sepsis 68 SUCCEED trial 68 ANCHOR trial 68 Pivotal Trial 68 multicentre randomized controlled 68 reduce serum phosphate 68 Phase 2a clinical 68 Oral Calcitonin 68 First Patient Dosed 68 hypoxia activated prodrug 68 Randomized Phase 68 phase IIb 68 alvespimycin 68 INCB# [001] 68 compound KOS 68 Golimumab 68 ABSORB clinical 68 TransVax 68 Intervention Effectiveness 68 relapsing remitting MS RRMS 68 ongoing Phase 1b 68 Ceflatonin R 68 Sapacitabine 68 generation PNP inhibitor 68 diabetic neuropathic pain 68 Trial Evaluating 68 recurrent metastatic ovarian cancer 67 Phase III Clinical Trial 67 Phase III confirmatory 67 kidney urologic 67 Dalbavancin 67 R sorafenib tablets 67 blinded randomized placebo controlled 67 CIMZIA TM certolizumab pegol 67 RhuDex ® 67 treatment naïve genotype 67 Phase III Pivotal 67 injectable enzyme 67 Phase #b/#a 67 Ocrelizumab 67 phase IIb trial 67 phase III isavuconazole 67 including eniluracil ADH 67 Initiated Phase 67 Genasense ® 67 antibody MAb 67 CTAP# Capsules 67 de novo kidney transplant 67 interferon gamma 1b 67 reslizumab 67 confirmatory Phase III 67 delivers fluocinolone acetonide FA 67 mertansine 67 Phase Ib 67 Phase 2b clinical 67 thetreatment 67 Phase IIb clinical 67 Forodesine HCl 67 Initiate Phase III 67 oral picoplatin 67 TG MV 67 phase IIb study 67 CA9 SCAN 67 Dacogen injection 67 volociximab 67 number NCT# ClinicalTrials.gov 67 recombinant PSMA vaccine 67 Second Pivotal Phase 67 APPRAISE 67 Phase 2b kidney transplant 67 Phase #/#a 67 phase IIb III 67 Delcath Phase III 67 Fx #A 67 non nucleoside inhibitor 67 Phase Ib study 67 P#X# antagonist 67 LUX Lung 67 JAK2 Inhibitor 67 multicenter randomized controlled 67 BR.# 67 novel oral anticoagulant 67 By JENNIFER LEARN 67 multicenter multinational 67 evaluating Actimmune 67 Phase IIb Trial 67 Gentamicin Surgical Implant 67 Custirsen 67 CEQ# 67 Kamada AAT 67 Phase 1b trial 67 Pivotal Phase 67 ospemifene 67 Initiates Clinical 67 ADVANCE PD 67 Phase IIIb 67 vidofludimus 67 PDX pralatrexate 67 ALN VSP Phase 67 Successfully Completes Phase 67 IIa Clinical Trial 67 occlusion PAO 67 ENDEAVOR IV 67 Phase 2b clinical trials 66 rasagiline tablets 66 dose intramuscular 66 Archexin 66 HCD# [002] 66 highly purified pasteurized 66 assessing T DM1 66 Hedgehog Pathway Inhibitor 66 Crofelemer budesonide foam 66 Pafuramidine 66 CLARITY TIMI 66 miconazole Lauriad ® 66 Allovectin 7 66 SCIB1 66 Phase lll 66 Phase IIa trial 66 recurrent malignant glioma 66 orally administered inhibitor 66 R lenalidomide 66 successfully commercialize Iluvien 66 leading oral taxane 66 OvaRex ® MAb 66 Initiates Phase 2b 66 CCR5 mAb 66 catheter occlusion 66 severe hypercholesterolemia 66 Belimumab 66 pralatrexate injection folate analogue 66 evaluating satraplatin plus 66 Phase III HEAT 66 TBC# 66 Amoxicillin PULSYS Phase III 66 Granted Orphan Drug 66 FOLFOX6 chemotherapy regimen 66 tramiprosate Alzhemed TM 66 Amgen Neulasta ® 66 Anturol TM 66 Raptiva ® 66 MIST II 66 RECORD1 66 rheumatoid arthritis psoriatic arthritis 66 midstage clinical 66 Cimzia TM 66 Empatic ™ 66 EDEMA3 66 Randomized Double blind 66 azilsartan medoxomil 66 CB2 selective receptor agonist 66 CCR9 antagonist 66 HIV coinfected 66 Pegloticase 66 LUMINATE 66 Silodosin 66 Phase III placebo controlled 66 PANVAC VF 66 OMAPRO ™ 66 GVAX ® 66 Presents Positive 66 placebo controlled clinical 66 adult chronic ITP 66 Refractory Angina 66 Files IND 66 Telik logo TELINTRA 66 DASISION 66 Arzerra ofatumumab 66 TASKi3 66 sorafenib tablets 66 PROVENGE ® 66 unresectable malignant mesothelioma UMM 66 RhuDex 66 pivotal bioequivalence 66 RANK Ligand inhibitor 66 Multiple Ascending Dose 66 lomitapide 66 Recurrent Glioblastoma 66 oral ghrelin agonist 66 First Patient Enrolled 66 IMA# 66 CYT# potent vascular disrupting 66 BCIRG 66 Receives Orphan Drug Designation 66 placebo controlled multicenter 66 REVIVE Diabetes 66 class mGluR5 inhibitor 66 GLPG# 66 ADVANCE ILLUMINATE 66 dimebon latrepirdine 66 Preclinical Models 66 Lupus Nephritis 66 Deferiprone 66 cathepsin K inhibitor 66 candidate XP# 66 evaluating satraplatin 66 oral Janus kinase 66 multicenter randomized placebo controlled 66 Tykerb lapatinib 66 CATIE AD 66 XL# SAR# 66 apricitabine ATC 66 dirucotide MBP# 66 orally inhaled migraine 66 ACCEDE 66 MKC# MKC# PP 66 Motesanib 66 Phase III Trial 66 Pivotal Clinical Trial 66 bone marrow reticulin deposition 66 lumiliximab 66 Pagoclone 66 Study Evaluating 66 Vitrasert R 66 phase IIIb 66 relapsed MM 66 Roche Actemra 66 Ixempra 66 VESTASYNC 66 PEGylated docetaxel 66 GetGoal Phase III 66 EchoCRT 66 phase Ib 65 Zenvia ™ 65 6 sulfatase 65 Cloretazine 65 Phase III metastatic melanoma 65 Remission Maintenance 65 confirmatory clinical 65 NVA# 65 evaluating mipomersen 65 acetonide FA 65 YONDELIS 65 Patient Enrollment 65 Ridaforolimus 65 UPLYSO 65 Canvaxin 65 Panzem R NCD 65 systemic anaplastic large 65 SinuNase TM 65 unique alkylating agent 65 AMD# [002] 65 SAR# [004] 65 oral dual endothelin 65 Clinical Trial Evaluating 65 SNT MC# 65 toenail onychomycosis 65 CLARITY study 65 TRACON Pharmaceuticals 65 AFREZZA TM 65 IIa clinical 65 phase 2a 65 Hormone Refractory Prostate Cancer 65 SPRYCEL ® 65 novel therapeutic antibodies 65 ELACYT 65 Investigational Treatment 65 fostamatinib 65 Plicera 65 Excellarate TM 65 Phase 1b Clinical Trial 65 oncolytic virus therapies 65 Receives CE Marking 65 virus HCV protease inhibitor 65 PNP inhibitor 65 Ofatumumab 65 relapsed leukemia 65 OAB overactive bladder 65 multicenter Phase 65 evaluating picoplatin 65 GTC recombinant form 65 personalized cellular immunotherapy 65 Ophena TM 65 essential thrombocythemia ET 65 GVAX R 65 Initiates Clinical Trial 65 budesonide foam 65 GW# [003] 65 GERD migraine headaches 65 immunotherapeutic agent 65 3 registrational trial 65 multicenter Phase III 65 triggers apoptosis programmed 65 Adjuvant Treatment 65 Prednisone Against Refractory 65 Phase IIb clinical trials 65 PrevOnco 65 seliciclib CYC# 65 IMPACT DCM clinical 65 docetaxel Taxotere R 65 humanised monoclonal antibody 65 Clinical Trial Results 65 Phase III psoriasis 65 AAG geldanamycin analog 65 Phase Ib clinical trials 65 recurrent glioblastoma multiforme 65 BRILINTA 65 HGS ETR1 mapatumumab 65 metaglidasen 65 Completes Patient Enrolment 65 Medidur TM FA 65 Patients Treated With 65 Phase III Psoriasis 65 confirmatory Phase 3 65 Somatuline R Depot 65 bile duct tumor 65 Phase III AFFIRM 65 Troxatyl 65 fidaxomicin Phase 65 NSABP C 65 oral proteasome inhibitor 65 Vicinium TM 65 IMPDH inhibitor 65 methylnaltrexone bromide 65 Completes Enrollment 65 Cannabinor 65 pharmacokinetic PK study 65 CALGB # [002] 65 Diabetic Macular Edema 65 myelodysplastic myeloproliferative diseases 65 Phase 2b Trial 65 relapsed multiple myeloma 65 novel nucleoside analog 65 Relapsed Refractory 65 Acetavance TM intravenous acetaminophen 65 BARACLUDE R 65 liver resection surgeries 65 Xelox 65 ELADUR ™ 65 humanized therapeutic 65 albiglutide 65 CEL SCI Phase III 65 elotuzumab 65 registrational trial 65 PDE4 inhibitor 65 TASKi2 65 Systemic Sclerosis 65 heFH 65 GAMMAGARD 65 Elotuzumab 65 TACI Ig 65 selective androgen receptor modulator 65 Phase IIb kidney transplant 65 opioid induced bowel dysfunction 65 PHX# 65 Nexavar ® 65 Vaccine Adjuvant 65 CRMD# 65 Phase 2a Clinical Trial 65 Deforolimus 65 oral deforolimus 65 SinuNase ™ 65 Pivotal Study 65 vapreotide acetate 65 Romiplostim 65 TNFerade ™ 65 Relapsed Multiple Myeloma 65 bardoxolone 65 LabCorp conducts clinical 65 Fovea Pharmaceuticals subsidiary 64 Heterozygous Familial Hypercholesterolemia 64 steroid refractory GvHD 64 bevirimat Study 64 ILUVIEN ® 64 memantine HCl 64 HCV NS5B polymerase 64 Glufosfamide 64 Hepatitis C Antiviral 64 Prestara 64 LHRH antagonist 64 CONQUER OB 64 Syncria albiglutide 64 pivotal Phase III 64 generation URAT1 inhibitor 64 antiretroviral naïve 64 Eniluracil 64 chronic myocardial ischemia 64 telomerase therapeutic 64 ToGA 64 selective A2A adenosine receptor 64 hoFH 64 trastuzumab DM1 T DM1 64 XYOTAX TM 64 Nipent R 64 Phase III TRIST 64 PFO migraine 64 Auxilium Pharma 64 dasatinib Sprycel ® 64 relapsed refractory multiple myeloma 64 Antibody Drug Conjugate 64 Demonstrates Positive 64 includes TOLAMBA TM 64 multicenter prospective 64 Androxal TM 64 CIMZIA TM 64 IIa trial 64 ONCONASE R 64 dose escalation phase 64 Peginterferon alfa 2b 64 Testosterone MDTS ® 64 signal detection CTSD 64 investigational monoclonal antibody 64 Submits IND 64 Randomized Clinical Trials 64 R#/MEM # 64 Prostate Cancer Vaccine 64 Alemtuzumab 64 brivanib 64 dependent kinase inhibitor 64 Temsirolimus 64 OvaRex R 64 PROTECT AF 64 VICTOR E1 64 Luveniq 64 Prochymal TM 64 COMFORT II 64 DIRECT Trial 64 oral rivaroxaban 64 Selective Electrochemical Tumor Ablation 64 Hepatitis C HCV 64 Namenda Memantine HCl 64 Tanespimycin 64 Fibrin Pad 64 Rilonacept 64 Phase III ADT 64 Thiarabine 64 Glatiramer Acetate 64 resistant hormone refractory 64 LEVADEX TM 64 metastatic hormone refractory 64 deforolimus 64 Phase IIIb study 64 MIVI III 64 develop HBV reactivation 64 Ganite ® 64 HEPLISAV TM 64 XL# XL# XL# 64 topical gel formulation 64 IMiDs ® 64 Tesetaxel 64 Dose Escalation 64 Diamyd R 64 subcutaneous PRO 64 Tezampanel 64 confirmatory Phase IIIb 64 Novel Oral 64 DEB# 64 metastatic castrate resistant 64 Proellex TM 64 indolent follicular non 64 Submits Biologics License Application 64 IMC #B 64 recurrent metastatic 64 Valtropin 64 MOVIPREP R 64 StemEx 64 comparing alemtuzumab 64 label Lipofen R 64 Empatic TM 64 PORxin TM platforms 64 relapsing multiple sclerosis 64 LEVADEX ™ 64 ZOLINZA 64 huC# DM4 64 elacytarabine 64 Budesonide foam crofelemer 64 Oglemilast 64 Aplidin 64 Perforomist ™ Inhalation Solution 64 Laquinimod 64 Vascular Disrupting Agent 64 inhaled AAT 64 investigational protease inhibitor 64 Callisto initiated 64 Prolongs Survival 64 Albugon 64 Nasdaq HALO 64 TMC# C# 64 nucleotide analogue 64 allosteric modulator PAM 64 Allovectin 7 ® 64 telomerase inhibitor drug 64 ThermoDox ® clinical 64 hyaluronidase enzyme 64 INTERCEPT red 64 PD LID 64 TRANSDUR ® 64 Virulizin ® 64 generation purine nucleoside 64 smoldering multiple myeloma 64 Afatinib 64 Mipomersen 64 QNEXA ® 64 NV1FGF 64 Bicifadine 64 BENLYSTA ® 64 metastatic castration resistant 64 Romidepsin 64 Plecanatide 64 Amigal TM 64 KRYSTEXXA TM pegloticase 64 Dose Ranging Study 64 riociguat 64 clinical trials Archexin 64 subcutaneous formulation 64 VIVITROL ® 64 Investigational Oral 64 hyperphenylalaninemia HPA due 64 Teplizumab 64 TRACON Pharmaceuticals Inc. 64 initiated Phase 1b 64 novel synthetic PEGylated 64 TRANSDUR ™ 64 KRN# 64 phase III ACCLAIM 64 BioNumerik 64 Ceflatonin 64 fosbretabulin 64 Phase 1b 64 GENASIS clinical 64 TransVax ™ 64 Phase IIB clinical 64 Eculizumab 64 gastrin analogue TT 64 Oral NKTR 64 GATTEX ™ 64 IV APAP 64 Serostim ® 64 Confirmatory Phase 64 Myelodysplastic Syndrome MDS 64 RNAi Therapeutic 64 multicenter randomized Phase 64 WX UK1 64 Randomized Double Blind 64 PI3K/Akt pathway inhibitor 64 PEGylated Fab fragment 64 Randomised 64 Oracea TM 64 Onyx Pharmaceuticals Announces 64 Prostate AdenoCarcinoma Treatment 64 Zalypsis 64 solid tumors ZYBRESTAT 64 ACTEMRA TM 64 generation DACH Platinum 64 Diamyd Medical Diamyd 64 Active Ulcerative Colitis 64 Syncria R 64 Dose Ranging 64 Saxagliptin 64 metastatic renal cell 64 Orphan Status 64 Completes Dosing 64 PRESEPT 64 IMiDs ® compound 64 Clolar ® 64 Allovectin 7 R 64 Prospective Randomized 64 Cetrorelix 64 Phase III randomized controlled 64 omacetaxine mepesuccinate 64 Telik Announces 64 Randomized controlled 64 TAXUS Element Paclitaxel Eluting 64 advanced metastatic prostate 64 oral dihydropyrimidine dehydrogenase DPD 64 tiapamil 64 personalized dendritic cell 64 generation Hsp# inhibitor 64 STRIDE PD 64 hematological malignancy 64 biologic antibody 64 MT#/MEDI-# 64 Corlux 64 PSMA ADC 64 Nasdaq PGNX today 64 Dementia Related Psychosis 64 controlled multicenter 64 GATTEX TM 64 Tipranavir 64 Annamycin 64 Alvesco R 64 OncoVex 64 Pruvel TM 64 anti VEGF aptamer 64 docetaxel Taxotere ® 64 Brentuximab Vedotin SGN 64 JAK#/JAK# inhibitor CYT# 63 apomorphine hydrochloride 63 Pulmonary Arterial Hypertension 63 Phase Ia 63 Besivance 63 ZALBIN 63 eritoran 63 autologous cellular immunotherapy 63 Teriflunomide 63 investigational antiplatelet agent 63 Simulect 63 GRN# 63 initiate Phase 1b 63 confirmatory pivotal 63 castrate resistant prostate cancer 63 Elagolix 63 Sudhir Agrawal D.Phil 63 ORAL Sync 63 ZYBRESTAT fosbretabulin 63 Treatment Experienced 63 CUSTOM III 63 MEK Inhibitor 63 delta opioid receptor 63 Advaxis Phase 63 EOquin TM 63 JAK inhibitor 63 Ecallantide 63 Phase III clinical 63 Pruvel ™ 63 Quinamed 63 IMPACT DCM 63 Val HeFT 63 adalimumab Humira 63 galiximab 63 octreotide implant 63 Phase III ThermoDox 63 next generation URAT1 63 PGL# 63 intravesical infusion therapy 63 generation rotary VAD 63 treat chronic sinusitis 63 Denufosol 63 Diamyd r 63 GENASIS 63 blinded placebo controlled 63 dual endothelin receptor antagonist 63 lexidronam injection 63 nasal calcitonin product 63 Aptivus ® 63 Amgen Neulasta R 63 Teva Provides Update 63 By JAMAAL ABDUL 63 NP2 Enkephalin 63 faropenem medoxomil 63 Anti PlGF 63 Xeloda ® 63 approved incretin mimetic 63 lead Aganocide compound 63 oral salmon calcitonin 63 Perifosine KRX 63 RhuDex R 63 Phase 2a Trial 63 Intravitreal 63 Glybera R 63 Fibrillex TM 63 OMP #R# 63 either acutely decompensated 63 CHARM Added 63 opioid naive 63 RhuDex TM 63 ORENCIA R 63 Cloretazine R VNP#M 63 Initiate Clinical Trial 63 lenalidomide Revlimid R 63 ThermoDox R 63 CONBRIZA 63 TRO# 63 commercialize CorMedix drug 63 Muraglitazar 63 Albuferon TM 63 novel tubulin binding 63 Tarceva TM 63 RELOVAIR ™ 63 Ribavirin causes 63 Phase IIA 63 Pazopanib 63 IL# PE#QQR 63 Phase IIa trials 63 AKT inhibitor 63 Ostabolin C TM 63 multicenter phase 63 CIMZIA R 63 imetelstat GRN#L 63 refractory metastatic colorectal cancer 63 Phase 2b Study 63 Aeolus Pharmaceuticals Announces 63 ExTRACT TIMI 63 Diamyd ® 63 Tesmilifene 63 undergoing elective percutaneous 63 TMC# [002] 63 developing Bicifadine serotonin 63 RE LY ® 63 evaluating T DM1 63 Microplasmin 63 Toremifene 63 radiation sensitizer 63 Vernakalant 63 Soliris TM eculizumab 63 candidate CRLX# 63 Fodosine 63 herpetic keratitis 63 Curaxin CBLC# 63 oral prodrug 63 TAXUS ATLAS 63 tolevamer 63 Genasense ® oblimersen 63 Bucindolol 63 Commences Phase 63 Pharmacokinetics PK 63 atypical Hemolytic Uremic Syndrome 63 AIR CF2 63 BiTE R 63 Civacir 63 Mg Usa 63 HuCAL antibodies 63 biliary tract cancer 63 forodesine hydrochloride 63 placebo controlled Phase 63 oral methylnaltrexone 63 EURIDIS 63 TRX1 63 Phase IIa 63 Bosutinib 63 Naive Patients 63 2 methoxyestradiol 63 Pralatrexate 63 Raptiva R 63 Inc. www.micromet inc.com 63 Traficet EN 63 neuropathic pain spasticity 63 Tovaxin TM 63 Entereg TM 63 Phase III randomized 63 aclidinium bromide 63 Tolvaptan 63 registrational 63 BENLYSTA TM 63 Tuberculosis Vaccine 63 IG HCR ;) CO 63 oxypurinol 63 VELCADE melphalan 63 SYCREST 63 GEM OS1 63 brand ciclesonide HFA 63 Zoraxel 63 acute peripheral arterial 63 BrachySil TM 63 AEG# 63 PRIMO CABG 63 NO# [002] 63 psoriatic arthritis PsA 63 demonstrated antitumor activity 63 REALITY Trial 63 ALN HPN 63 huN# DM1 63 systemic juvenile idiopathic 63 Dupuytren Contracture 63 IMPACT IMmunotherapy 63 Immunotherapeutic 63 systemic Phase 1b 63 REG1 Anticoagulation System 63 Syndax Pharmaceuticals Inc. 63 initiate Phase IIb 63 RE MODEL 63 Amrubicin 63 PLX STROKE targeting 63 Multicenter Randomized 63 #mg ATC 63 Patient Enrolment 63 inhaled formulation 63 Mylan Receives Approval 63 PROTEGE 63 TAXUS Element Stent System 63 OncoVEX GM CSF 63 RTP #i 63 Newly Diagnosed Multiple Myeloma 63 designated HVTN 63 AERAS-#/Crucell Ad# 63 receptor tyrosine kinase inhibitor 63 stated Michelle Berrey 63 LEUKINE 63 PLK1 SNALP 63 Files Investigational 63 Maribavir 63 lorvotuzumab mertansine 63 Sprycel dasatinib 63 Investigational Compound 63 orally ingestible insulin 63 pseudobulbar affect PBA 63 Maximum Tolerated Dose MTD 63 SPIRIT FIRST 63 hereditary deficiency 63 MYTHOS trial 63 product TNFerade TM 63 oral nucleoside analogue 63 LHRH receptor positive 63 Arimoclomol 63 Certolizumab pegol 63 REMINYL ® 63 Cimzia ® certolizumab pegol 63 ORAL Solo 63 oxymorphone ER 63 DDP# 63 Bavituximab 63 pediatric Crohn disease 63 ® bortezomib 63 advanced metastatic renal 63 DNAwithPap TM Test 63 Lysteda 63 controlled multicenter Phase 63 HGS ETR2 63 Prednisporin TM 63 Demonstrates Sustained 63 Telatinib 63 Phase IIb Clinical Trial 63 TOCOSOL Camptothecin 63 LAB CGRP 63 metastatic colorectal carcinoma 63 Nanobody R 63 acyclovir Lauriad ® 63 Fludara ® 63 label multicenter 63 SUPPRELIN R LA 63 StemEx R 63 Entereg R 63 Clinical Trial Investigating REOLYSIN 63 Acute Ischemic Stroke 63 VNP#M 63 initiate Phase IIa 63 Hematide ™ peginesatide 63 Vitaxin 63 dyskinesia PD LID 63 StaphVAX R 63 Dapagliflozin 63 alemtuzumab Campath 63 Genasense oblimersen sodium Injection 63 Neuvenge 63 fidaxomicin Phase 3 63 mGluR2 positive 63 Phase IIa Clinical Trial 63 Fast Track Status 63 sunitinib malate 63 Acute Exacerbations 63 Pivotal Phase II 63 Elesclomol 63 Hodgkin lymphoma HL 63 PEG SN# 63 Neo Bladder Augment 63 oral FTY# 63 cannabinor 63 5 fluorouracil leucovorin 63 miconazole Lauriad 63 bortezomib Velcade R 63 targeting miR 63 intravenous RSD# 63 OncoVEX 63 GEM OS2 63 ganetespib 63 Dermylex TM 63 alfa 2a 63 CDP# 63 HCV RESPOND 2 63 Aceon 63 cMET 62 tenofovir disoproxil fumarate Viread 62 DEEP AF 62 ZACTIMA 62 DermaVir Patch 62 Phase 1a 62 Dyloject TM 62 MEND CABG 62 Phase 2a trial 62 Receives Milestone Payment 62 Neulasta R 62 Nitazoxanide 62 metastatic colorectal 62 Presents Preclinical 62 Synta Announces 62 Commences Phase III 62 opioid induced constipation OIC 62 protein tyrosine phosphatase 1B 62 Nasdaq RDEA 62 investigational pan BCR 62 overactive bladder AA# 62 ALVESCO R 62 Long Term Efficacy 62 evaluating Xcytrin 62 HIV treatments Reyataz 62 glucokinase activator 62 VITAL Trial 62 squamous non 62 dose escalation Phase 62 plus Copegus R 62 INS# [001] 62 BLP# Liposome Vaccine 62 FDA Accepts 62 Zemplar Capsules 62 mRCC 62 landmark ATHENA 62 adjuvant colon cancer 62 developed preclinically 62 TransVax tm 62 null responder HCV 62 Shows Efficacy 62 compound PMX # 62 adecatumumab MT# 62 AIMM trial 62 Novolimus 62 Targretin capsules 62 Randomized Phase III 62 Mycophenolate Mofetil